10th Dec 2007 07:01
PuriCore Plc10 December 2007 PuriCore Receives Additional US Patent on Sterilox Systems to Control the Spread of Infectious Pathogens MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 10 December, 2007 - PuriCore (LSE:PURI), the life sciences company focused on the development andcommercialisation of its novel, safe antimicrobial technology, today announcedthat the US Patent and Trademark Office has granted PuriCore an additionalpatent for its Sterilox Systems. The new patent, US Patent No. 7,303,660, ispart of the same patent family as PuriCore's previously issued US Patent No.6,632,347, which covers an optimal process for operating PuriCore's Systems toprepare its disinfection solutions. PuriCore's technology is marketed currently in the US and UK as Sterilox FoodSafety Systems and Sterilox Endoscopy Systems, respectively. These SteriloxSystems produce hypochlorous acid, the same safe and effective antimicrobialsolution produced by the human body to fight infection. Leading US supermarketretailers and UK hospitals use PuriCore's Sterilox Systems to control the spreadof infectious pathogens. Greg Bosch, CEO of PuriCore, said: "Together, these patents protect PuriCore's core technology and further verifiesits standing as a leader and innovator in the field of infection control. Wecontinue to expand our broad intellectual property portfolio focused on safe andeffective antimicrobial solutions and devices for producing these solutions." About PuriCore PuriCore (London Stock Exchange: PURI) is a life sciences company focused ondeveloping and commercialising proprietary products that safely, effectively,and naturally kill contagious pathogens. PuriCore's technology provides asolution to a broad range of markets that depend upon controlling contamination,including food safety, medical device disinfection, wound therapy, andhospitality. The Company's proprietary technology mimics the human body'sproduction of the natural antimicrobial hypochlorous acid, which is highlyeffective in killing bacteria, viruses, and fungal spores. Deployinghypochlorous acid solutions as soaks, sprays, mists, and in other forms,PuriCore's technology is designed to limit the spread of infectious disease,including major public health threats of M. tuberculosis, MRSA, E.coli,norovirus, avian influenza, HIV, polio virus, Helicobater pylori, andLegionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices inStafford, UK. To receive additional information on PuriCore, please visit our web site atwww.puricore.com, which does not form part of this press release. Contacts:Ben Brewerton Greg Bosch, CEOFD Keith Goldan, CFO020 7269 7279 PuriCore +1 484 321 2700 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
RLM.L